Neither anticoagulant nor nonanticoagulant heparin affects monocrotaline lung injury.
The administration of monocrotaline to rats causes pulmonary vascular leak within 1 wk followed in 2-3 wk by perivascular proliferation and fatal pulmonary hypertension. Possibly blocking the proliferation might block the pulmonary hypertension, providing insight into its mechanism. Because heparin, given as an antiproliferative agent, reduced hypoxic pulmonary hypertension in mice, it might also block monocrotaline-induced pulmonary hypertension. Alternatively, anticoagulation could worsen the lung injury. We found that heparin (300 and 600 U/kg sc twice daily) inhibited clotting in rats given monocrotaline but did not change the vascular leak, the right ventricular pressure, the right ventricular hypertrophy, the increased medial thickness of the pulmonary arterioles, or the production of a slow-reacting substance of anaphylaxis-like material by the lungs. A nonanticoagulant heparin fragment (2 mg/kg sc twice daily), given to avoid anticoagulation also did not influence the monocrotaline injury. Thus neither anticoagulant nor nonanticoagulant heparin either attenuated or worsened the measured effects of monocrotaline.
D000818:Animals; D000925:Anticoagulants / Q000627:therapeutic use*; D001158:Arteries / Q000473:pathology; D001794:Blood Pressure; D002199:Capillary Permeability; D006493:Heparin / Q000627:therapeutic use*; D008168:Lung / Q000378:metabolism; D008171:Lung Diseases / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D016686:Monocrotaline; D010314:Partial Thromboplastin Time; D011652:Pulmonary Circulation; D011763:Pyrrolizidine Alkaloids; D051381:Rats; D011919:Rats, Inbred Strains; D013189:SRS-A / Q000378:metabolism; D013918:Thrombin Time
D000925:Anticoagulants; D011763:Pyrrolizidine Alkaloids; D013189:SRS-A; D016686:Monocrotaline; D006493:Heparin